Study on Malignancy, Staging, and Grading for Gastrointestinal Stromal Tumors

Y. Hou,X. Zhu,S. Lu,Y. Zhou,J. Xu,Y. Ji,J. Hou,W. Qi,Y. Shi,Y. Tan
DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.21521
IF: 45.3
2008-01-01
Journal of Clinical Oncology
Abstract:21521 Background: The biologic behavior spectrum of gastrointestinal stromal tumors (GISTs) exhibit from indolent to highly aggressive. Although risk stratification was proposed by the NIH criteria according to tumor size and mitoses, limitations of the criteria exist, and better risk factors are needed. Methods: A retrospective review was conducted in 840 patients who had undergone surgical resection of primary GISTs from 12 hospitals. GISTs were classified as malignant according to gross spread including liver metastasis, peritoneal dissemination as well as microscopic spread including lymph node metastasis, vascular, fatty, nerve and mucosa infiltrating, or death, the left recorded as biologic behavior uncertain. Results: Significantly different factors for malignancy identified in the two groups were 5 morphological parameters including mitotic count≥10 per 50HPF (P=0.000), muscularis propria infiltrating (P=0.000), coagulative necrosis (P=0.002), ancient-coin-like growth pattern (P=0.006), and nuclear severe atypia (P=0.029). A new classification system based on a combination of these 2 gross spread, 5 microscopic spread and 5 parameters in situ were developed. Among 840 patients, 485 were malignant, 355 were benign-borderline. The disease free survival (DFS) showed significant difference between borderline and malignant GISTs, between presence and absence of gross spread, between presence and absence of microscopic spread, DFS was associated with the number of parameters predictive of malignancy in GISTs without gross spread. Conclusions: Twelve parameters were predictive of malignancy, malignant GISTs could be divided into clinical stage II and I, pathological stage II and I according to presence or absence of gross and microscopic spread, malignant degree could be graded according to the number of malignant parameters. The clinical stage, grade, mitotic count ≥10/50HPF were the most important prognostic parameters in malignant GISTs. It is expected, the new approach and results will be of value in imatinib therapy. No significant financial relationships to disclose.
What problem does this paper attempt to address?